Key facts
- This page summarizes Ankur Dhingra's Form 4 filing for Summit Therapeutics Inc. (SMMT).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 27 Mar 2024, 20:27.
Ankur Dhingra - 26 Mar 2024 Form 4 Insider Report for Summit Therapeutics Inc. (SMMT)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- SMMT
- Reported as of
- 26 Mar 2024
- Net transaction value
- +$375,000
- SEC form
- 4
- Accepted by SEC
- 27 Mar 2024, 20:27:03 UTC
- Prior SEC filing
- 13 Dec 2023
- Next SEC filing
- 24 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ankur Dhingra
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ankur Dhingra filed Form 4 for Summit Therapeutics Inc. (SMMT) on 27 Mar 2024.
Change
- Previous filing in this sequence was filed on 13 Dec 2023.
- Current net transaction value: +$375,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SMMT
transaction
Common Stock
Purchase
- Transaction value
- $375,000
- Shares
- +100,000
- Change %
- +39%
- Price
- $3.75
- Shares after
- 354,958
- Date
- 26 Mar 2024
- Ownership
- By Dhingra Family Revocable Trust
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.74 to $3.76 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F2
The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.